tirzepatide and graves disease Thyroid Eye Reactivates After Using Teprotumumab Tirzepatide and Graves' Disease: Safety

In another major analysis, researchers examined more than 30 million FDA adverse event reports to identify potential safety signals linked to GLP-1 drugs

A gynecologist or an endocrinologist can provide guidance on managing the hormonal shifts that occur during this phase of life

Key findings from the SURMOUNT-OSA trial The SURMOUNT-OSA trial evaluated tirzepatide versus placebo in adults with moderate-to-severe OSA (AHI 15) and obesity, including both CPAP users and non-users

Ceasovschih A, et al

This has been a long time coming

Some patients were given CONTRAVE and others received a placebo (pill with no medication)